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Protein homeostasis (proteostasis), the correct balance between production and
degradation of proteins, is essential for the health and survival of cells. Proteostasis
requires an intricate network of protein quality control pathways (the proteostasis
network) that work to prevent protein aggregation and maintain proteome health
throughout the lifespan of the cell. Collapse of proteostasis has been implicated in
the etiology of a number of neurodegenerative diseases, including amyotrophic lateral
sclerosis (ALS), the most common adult onset motor neuron disorder. Here, we review
the evidence linking dysfunctional proteostasis to the etiology of ALS and discuss how
ALS-associated insults affect the proteostasis network. Finally, we discuss the potential
therapeutic benefit of proteostasis network modulation in ALS.
Keywords: protein homeostasis, protein aggregation, amyotrophic lateral sclerosis (ALS), motor neuron disease,
autophagy, chaperonins, unfolded protein response (UPR), proteostasis
INTRODUCTION
The proteostasis network is a complex regulatory network that maintains proteostasis. The
proteostasis network consists of several pathways that control protein biosynthesis, folding,
trafficking, and clearance (degradation) and responds to specific protein stress pathways such as
the unfolded protein response (UPR) in the endoplasmic reticulum (ER), the mitochondrial UPR
and the cytosolic heat shock response (Figure 1).
Proteins are constantly turned over to ensure a steady supply of functional proteins. Newly
synthesized proteins fold into their specific three-dimensional shape co-translationally as the
nascent polypeptide chain emerges from the ribosome. The specific three-dimensional structure
of a protein, which is in part determined by its amino acid sequence, is crucial to its function.
A number cytosolic and ER resident folding factors aid the complex process of protein folding, such
as chaperones and co-chaperones of the heat shock protein (Hsp) family, peptidyl prolyl cis/trans
isomerases, and oxidoreductases (reviewed in Braakman and Bulleid, 2011; Kim et al., 2013).
Nevertheless, the nature of protein folding and the cellular environment is such that unfolding
and misfolding are relatively common events. Upon protein misfolding, specific protein stress
pathways such as the heat shock response and UPR are activated to boost chaperone levels and aid
refolding or to stimulate removal of terminally misfolded proteins to prevent protein aggregation
and proteotoxic stress.
Eukaryotic cells have two major pathways of protein degradation: the proteasome and the
lysosome. The proteasome is a multimeric ATP-dependent protease complex that selectively
recognizes ubiquitinated substrates. Degradation by the proteasome requires protein unfolding and
relies on chaperones to prevent proteins from aggregating (reviewed in Hershko and Ciechanover,
1998). Autophagy denotes the delivery of cytoplasmic components to the lysosome. Autophagy
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can be separated into three types depending on how the substrate
is delivered to the lysosome: chaperone mediated autophagy
(CMA), microautophagy and macroautophagy, herein termed
autophagy (reviewed in Bento et al., 2016). Aggregated proteins
are mostly removed by autophagy, a process that is also called
aggrephagy (reviewed in Lamark and Johansen, 2012).
Ultimately proteostasis collapse due to failure of the
proteostasis network to refold, degrade or effectively sequester
and compartmentalize aggregation-prone, misfolded and
potentially toxic protein species is deleterious to cells. Neuronal
cells appear to be particularly vulnerable to disturbances in
proteostasis because they are long-lived post-mitotic cells
that are not able to dilute out protein aggregates during cell
divisions (Son et al., 2012). Furthermore, as the ability of cells to
maintain proteostasis declines with aging it is not surprising that
aberrant protein folding and aggregate deposition in neurons
is a common feature of age-associated neurodegenerative
disease.
FIGURE 1 | The proteostasis network and ALS. Protein folding occurs co-translationally at the ribosome with the aid of molecular chaperones, including Hsp70.
Correct folding is essential for protein function. Protein folding and refolding continues in the cytosol and the endoplasmic reticulum (ER) lumen. Chronic misfolding in
the cytosol leads to targeting of misfolded substrates to the ubiquitin proteasome system (UPS). Poly-ubiquitin chains target substrates for degradation by the
proteasome. Overwhelming of the UPS can lead to poly-ubiquitinated aggregate formation, which are cleared by the autophagosome–lysosome pathway. Chronic
misfolding in the ER leads to the induction of ER stress and activation of the unfolded protein response (UPR). The UPR leads to altered gene transcription,
upregulating ER associated degradation (ERAD) and autophagy. The proteostasis network seeks to restore protein homeostasis, but failure of the pathway leads to
the aggregation of potentially toxic species. Disruption of the proteostasis network is prevalent in the pathogenesis of ALS. A large number of ALS-associated genes
(indicated in red) directly or indirectly regulate the proteostasis network. In addition, some ALS-associated proteins such as FUS, TDP-43, and SOD1 are also
substrates of these pathways. For further details please refer to the main text.
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Here, we review the evidence linking dysfunctional
proteostasis to the etiology of amyotrophic lateral sclerosis
(ALS) and discuss how ALS-associated insults affect the
proteostasis network.
LOSS OF PROTEIN HOMEOSTASIS
IN ALS
ALS is a progressive adult onset motor neuron disease
characterized by selective degeneration of upper and lower
motor neurons in the motor cortex, brainstem, and spinal
cord. The progressive deterioration of the motor system leads
to muscle wasting, paralysis and eventual premature death,
most commonly due to respiratory failure. Death occurs
on average within approximately 3 years of symptom onset
(reviewed in Kiernan et al., 2011). The causes of ALS are
numerous and complex, but remain incompletely understood.
Proposed mechanisms include, among others, oxidative stress,
mitochondrial dysfunction, defective axonal transport, RNA
toxicity, excitotoxicity, neuroinflammation, and loss of protein
homeostasis (reviewed in Ferraiuolo et al., 2011; De Vos
and Hafezparast, 2017). While most ALS cases have no clear
genetic basis (sporadic ALS), approximately 10% of ALS is
inherited, usually in an autosomal dominant fashion (familial
ALS). Studies of familial ALS cases have revealed multiple
ALS-associated genes. While these genes play significant
roles in a range of essential cellular processes including
RNA processing, mitochondrial function and endosomal
trafficking, a significant number of these have been linked
to different aspects of the proteostasis network (Table 1 and
Figure 1).
There is a significant clinical, neuropathological, and genetic
overlap between ALS and frontotemporal dementia (FTD), a
common form of early onset dementia that is characterized by
changes in behavior and personality or language dysfunction.
Up to 15% of ALS cases are clinically diagnosed with FTD
and approximately 50% of FTD cases display motor symptoms
(reviewed in Swinnen and Robberecht, 2014).
Neuropathological Evidence for
Dysfunctional Proteostasis in ALS
Intracellular proteinaceous inclusions are a hallmark
neuropathological feature of ALS. Inclusions are found in
both degenerating neurons and surrounding glia (Piao et al.,
2003; Nishihira et al., 2008; Zhang et al., 2008) and are found not
only in the brainstem and spinal cord, but also in the cerebellum,
hippocampus, and the frontal and temporal lobes (reviewed in
Al-Chalabi et al., 2012). The most common inclusions are of
ubiquitinated proteins, which are found in both the upper and
lower motor neurons (Neumann et al., 2006), and are suggestive
of defects in protein turnover (Blokhuis et al., 2013). Based on
their morphology, these ubiquitinated inclusions are subdivided
into skein-like inclusions that are filamentous in structure, and
rounded Lewy body-like inclusions (Leigh et al., 1988; Lowe
et al., 1988; Kato et al., 1989). ALS-associated ubiquitinated
inclusions are typically positive for p62/sequestosome-1
(King et al., 2011), a ubiquitin binding protein involved in
autophagy (see below). In the vast majority of sporadic and
familial ALS cases ubiquitinated protein inclusions are positive
for Tar DNA-binding protein of 43 kDa (TDP-43) (Arai et al.,
2006; Neumann et al., 2006). TDP-43 was also identified as
the pathological protein in frontotemporal lobar degeneration
(FTLD)-related ubiquitinated inclusions, supporting the idea
that ALS and FTD reside on the same spectrum of disease (Arai
et al., 2006; Neumann et al., 2006; reviewed in Swinnen and
Robberecht, 2014). Not only are aggregates of wild type TDP-43
found in nearly all cases of disease, but mutations in the TARDPB
gene that encodes TDP-43 are also causative for ALS (Kabashi
et al., 2008; Sreedharan et al., 2008). ALS-associated mutations
in TARDBP lead to cytoplasmic TDP-43 mislocalisation and its
aberrant incorporation into neurotoxic ubquitinated cytoplasmic
aggregates (Barmada et al., 2010). Inhibition of the proteasome
or autophagy leads to the aggregation of TDP-43 (Urushitani
et al., 2010; Wang et al., 2010) (see below).
Although the majority of ubiquitinated inclusions are
immunoreactive for TDP-43, notable exceptions are the
inclusions found in ALS patients with mutations in SOD1
or FUS, which are negative for ubiquitinated TDP-43 but
immunoreactive for mutant aggregated Cu/Zn superoxide
dismutase (SOD1) and fused in sarcoma protein (FUS)
respectively (Watanabe et al., 2001; Wang et al., 2002; Mackenzie
et al., 2007; Kwiatkowski et al., 2009; Vance et al., 2009). Similar
to TDP-43, mutant FUS demonstrates abnormal cytoplasmic
redistribution and aggregation (Kwiatkowski et al., 2009;
Vance et al., 2009; Dormann et al., 2010). Further familial
ALS-associated mutant proteins that are prone to aggregation
are valosin containing protein (VCP), dynactin-1 (DCTN1),
optineurin (OPTN) and ubiquilin-2 (UBQLN2) (Levy et al.,
2006; Maruyama et al., 2010; Deng et al., 2011; Koppers et al.,
2012).
C9orf72-related ALS presents an outlier to classical ALS
pathology. In C9orf72-related ALS TDP-43 proteinopathy is
present, but additional inclusions are p62/sequestosome-1 and
ubiquitin positive, yet devoid of TDP-43 (Al-Sarraj et al., 2011;
Cooper-Knock et al., 2012; Mackenzie et al., 2014). In addition,
the GGGGCC repeat expansion in the C9ORF72 gene gives rise to
five species of dipeptide protein (DPR) inclusions (GA, GR, GP,
PR, and PA) by repeat-associated non-AUG translation (Mann
et al., 2013; Mori et al., 2013; Mackenzie et al., 2014).
Other ALS-associated inclusions include Bunina bodies
(found post-mortem in approximately 86% of sporadic ALS
patients) and hyaline conglomerate inclusions (Bunina, 1962;
Kato et al., 1989; Murayama et al., 1989). Bunina bodies are
comprised of cystatin C, transferrin, peripherin, and sortilin-
related receptor CNS expressed 2 (SORCS2) and are found in
the surviving lower motor neurons within the brain stem and
spinal cord (Okamoto et al., 1993; Piao et al., 2003; Mizuno et al.,
2006, 2011; Mori et al., 2015). They also contain small organelle
fragments such as vesicles and ER (Okamoto et al., 2008; Kimura
et al., 2014). Bunina bodies and TDP-43 positive inclusions have
been shown to co-localize, and TDP-43 inclusion prevalence
increased with Bunina body presence suggesting a synergy
between the two inclusion types (Mori et al., 2010, 2014). Hyaline
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conglomerate inclusions are comprised of phosphorylated and
non-phosphorylated neurofilaments (Hirano et al., 1984; Munoz
et al., 1988; Hays et al., 2006) and their formation is possibly
linked to defective axonal transport (Munoz et al., 1988; Ackerley
et al., 2000, 2003).
The typical occurrence of these protein aggregates in
ALS patients strongly suggest a collapse of proteostasis
in ALS. These proteinaceous inclusions are replicated in
a number ALS-associated animal models, including mutant
SOD1, FUS, and TDP-43 transgenic mice. The fact that these
models are able to effectively replicate some of the most
prevalent neuropathological features of ALS suggests that the
proteinaceous inclusions and aggregates are major contributors
to disease pathogenesis.
Genetic Evidence for Dysfunctional
Proteostasis in ALS
As mentioned above, about 10% of ALS cases are inherited,
usually in an autosomal dominant fashion (reviewed in Renton
et al., 2014). A number of familial ALS-associated proteins are
known to be involved in the proteostasis network, including
C9orf72, VCP, p62/sequestosome-1, ubiquilin-2, optineurin,
dynactin, and TANK binding kinase 1 (TBK1) (Table 1 and
Figure 1). The role of these genes in proteostasis is discussed in
detail in the following sections.
Altered Chaperone Function in ALS
Molecular chaperones assist protein folding and help maintain
proteins in their native folded state. In addition, they function in
proteostasis to facilitate protein unfolding and disaggregation,
and the targeting of terminally misfolded proteins for
degradation. In relation to neurodegeneration, perhaps the
key function of chaperones is to prevent protein aggregation
under conditions of stress. Altered chaperone function has been
implicated in ALS (Figure 2).
The presence of chaperones, such as heat shock cognate
protein of 70 kDa (Hsc70) and heat shock protein of 90 kDa
(Hsp90) in detergent-insoluble neuronal aggregates in the
SOD1G93A transgenic mouse model of familial ALS and
post-mortem human sporadic ALS cases indicates that altered
chaperone function may contribute to disease pathogenesis
(Watanabe et al., 2001; Basso et al., 2009; Bergemalm et al.,
2010). In cell based assays and mouse models, ALS mutant
SOD1G93A and G85R show increased interaction with a number
of chaperones, including Hsp70, suggesting that ALS-associated
mutant species may result in a depletion of available chaperones
TABLE 1 | Potential impact of ALS-associated genes on protein quality control.
ALS locus Gene Protein Potential consequence of mutation on protein homeostasis
ALS1 SOD1 Superoxide dismutase 1 Aggregate formation leading to depletion of available chaperones, induction of
ER stress due to impairment of UPR and ERAD, impaired UPS and autophagy
ALS2 ALS2 Alsin Reduced Vps34 activation and autophagosome formation
ALS5 SPG11 Spatacsin Reduced autophagosome–lysosome reformation
ALS6 FUS RNA-binding protein FUS Aggregate formation, reduced autophagy related gene expression and impaired
substrate delivery to autophagosome
ALS8 VAPB Vesicle-associated membrane
protein-associated protein B
Defective UPR activation and increased ER stress
ALS10 TARDBP TAR DNA-binding protein 43 Redistribution of TDP-43 to cytoplasmic aggregates, reduced autophagy
related gene expression and defective substrate delivery to autophagosomes
ALS11 FIG4 Fig4 Reduced autophagosome clearance
ALS12 OPTN Optineurin Impaired autophagy substrate recruitment to autophagosomes
ALS14 VCP Valosin-containing protein Impaired mitochondrial proteostasis and ERAD, defective UPS degradation,
and reduced autophagosome maturation
ALS15 UBQLN2 Ubiquilin-2 Defective substrate delivery to the proteasome and proteasomal clearance.
Impaired substrate delivery to autophagosomes
ALS16 SIGMAR1 Sigma non-opioid intracellular receptor 1 Dysfunctional ER–mitochondria communication, calcium dysfunction, and ER
stress
ALS17 CHMP2B Charged multivesicular body protein 2B Impaired endocytic trafficking, autophagosome–lysosome fusion and reduced
autophagic clearance
ALS-FTD1 C9orf72 C9orf72 Reduced functional protein, defective Rab-mediated trafficking and impaired
autophagy induction. Additional formation of DPR proteins from expanded
repeat
ALS DCTN1 Dynactin 1 (p150, glued homolog, Drosophila) Altered axonal transport and vesicle trafficking, impaired signaling endosome
trafficking and reduced autophagosome transport
ALS SQSTM1 p62/sequestosome-1 Impaired autophagy substrate recruitment to autophagosomes
ALS TBK1 TANK binding kinase-1 Reduced phosphorylation of autophagy receptors, reducing ubiquitin and
LC3-II binding capacity
Pathogenic variants of the proteins in this table have been linked to disrupted protein homeostasis (ref: http://alsod.iop.kcl.ac.uk/home.aspx; Abel et al., 2012). DPR,
dipeptide repeat; ER, endoplasmic reticulum; ERAD, endoplasmic reticulum associated degradation; LC3, microtubule-associated protein 1 light chain 3; UPR, unfolded
protein response; UPS, ubiquitin proteasome system.
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FIGURE 2 | Chaperone dysfunction in ALS. Protein folding occurs co-translationally at the ribosome. Correct folding and re-folding continues in the cytoplasm or
ER with the help of molecular chaperones and leads to correctly folded, fully functional proteins. Chaperone dysfunction has been implicated in ALS. Aggregating
ALS mutant SOD1 and mislocalised TDP-43 interact with chaperones of the heat shock protein family, namely Hsp70 and Hsp90. While the recruitment of
chaperones to the aggregates is likely a protective mechanism, their sequestration potentially depletes the levels of available chaperones, decreasing chaperone
folding activity, therefore leading to toxicity. The ALS-associated protein aggregates and other ALS-associated defects to the chaperone system are indicated in red.
For further details please refer to the main text.
and chaperone activity, therefore leading to cellular toxicity
(Tummala et al., 2005; Ganesan et al., 2007). Furthermore,
reduced levels of the chaperone alpha-B-crystallin (CRYAB)
and increased incorporation of other molecular chaperones,
including Hsc70, into the insoluble aggregate fraction are features
of a faster progressing phenotype in SOD1G93A transgenic mice
(Marino et al., 2015).
As discussed above, redistribution of wild type or mutant
TDP-43 to the cytoplasm and its aberrant inclusion into
ubiquitinated cytoplasmic aggregates is a hallmark of ALS
(Arai et al., 2006; Neumann et al., 2006). Interestingly, TDP-43
aggregates have been shown to interact with Hsp70 and Hsp90
under conditions of heat shock stress or reactive oxygen species
(ROS) insult (Chang et al., 2013; Udan-Johns et al., 2014;
Budini et al., 2015). The finding that activating Hsp70 reduces
the insoluble aggregates of TDP-43, suggests that chaperone
dysregulation could be a contributing factor to TDP-43 aggregate
formation and toxicity (Chang et al., 2013). In agreement with
this, knock-down of the molecular chaperones Hsp70 and Hsp90,
leads to increased aggregation of TDP-43 (Zhang et al., 2010),
while increasing levels of the small heat shock protein B8 (HspB8)
increased the solubility of mutant TDP-43 and reduced toxicity
(Crippa et al., 2010). Similarly, upregulation of the small heat
shock protein CG14207 was able to reduce neurotoxicity of full
length TDP-43 and the C-terminal fragment of TDP-43 in a
Drosophila model of ALS (Gregory et al., 2012). Overexpression
of Hsc70 in Drosophila also prevents the aggregation of FUS
protein into insoluble fractions (Miguel et al., 2012).
Thus, increased chaperone levels may provide a protective
mechanism in ALS. The reported upregulation of HspB1 and
HspB8 chaperone expression in the lumbar spinal cord of 39
ALS cases (4 of which were familial ALS cases) compared to
19 control samples may be an indication of such a protective
response (Anagnostou et al., 2010).
ER Stress, the UPR and ALS
Cells use stress sensors and inducible pathways to respond to
a loss of proteostatic control. One such pathway is the UPR,
an adaptive response to the accumulation of misfolded proteins
in the lumen of the ER (i.e., ER stress) (Figure 3). ER stress
induced by accumulation of unfolded proteins activates three
UPR pathways mediated by three ER membrane resident stress
sensors, protein kinase RNA-like ER kinase (PERK), inositol-
requiring protein 1 (IRE1) and activating transcription factor
6 (ATF6) (reviewed in Hetz, 2012). The UPR tries to restore
proteostasis by (i) attenuation of translation, (ii) induction
of chaperones to aid protein folding, and (iii) upregulation
of degradation pathways such as ER-associated degradation
(ERAD) and autophagy to remove misfolded proteins. If ER stress
Frontiers in Molecular Neuroscience | www.frontiersin.org 5 May 2017 | Volume 10 | Article 123
fnmol-10-00123 April 29, 2017 Time: 12:26 # 6
Webster et al. Protein Homeostasis in ALS
FIGURE 3 | Unfolded protein response in the ER leads to ER stress. The accumulation of protein aggregates is sensed by three ER-stress transducers: IRE1α,
PERK, and ATF6. ER stress causes IRE1α dimerisation, which activates its intrinsic RNAse activity and leads to alternative splicing of XBP1 mRNA. Spliced XBP1
forms a functional transcription factor. XBP1 increases expression of chaperone related genes and those involved in ERAD. PERK also dimerises due to ER stress.
PERK dimerization leads to phosphorylation of the eukaryotic initiation factor eIF2α, thus inhibiting general protein synthesis. Inhibition of protein synthesis allows the
translation of stress response transcription factor, ATF4. ATF4 increases expression of genes related to autophagy and apoptosis. Via the action of coat protein
complex II (COPII), ATF6 translocates from the ER membrane to the Golgi during ER stress where it is processed by the Site 1 (Sp1) and Site 2 (Sp2) proteases.
Cleavage produces a functional cytosolic fragment of ATF6. The ATF6 transcription factor induces expression of genes related to ERAD, but also XBP1, thereby
promoting UPR. Chronic ER stress and UPR activation indicates the cell has failed to respond to ER stress. Under such conditions all three ER stress transducers
lead to the increased expression of CHOP, which promotes apoptosis. For further details please refer to the main text.
is short-lived, the UPR restores proteostasis and the cell survives.
If in contrast ER stress persists, as for example in ALS, the UPR
triggers apoptosis and the cell is lost.
Multiple lines of evidence from ALS patients and models
suggest that ER stress may be a contributing factor to the
development of ALS (Figure 4). Amorphous, granular material
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FIGURE 4 | Endoplasmic reticulum stress the UPR and ALS. ALS-associated genes have been implicated in ER stress and the UPR. The ALS-associated
genes and their positions within the UPR pathway are indicated in red, as are other ALS-associated defects to the UPR. Briefly, ALS-associated protein aggregates,
including C9orf72-related DPR proteins, TDP-43 and SOD1, are sensed by the ER-stress transducers leading to chronic activation of the UPR, caspase-12 cleavage
and apoptosis, while disruption of ER/mitochondria contact sites leads to dysfunctional calcium homeostasis and, in turn, elevated ER stress. Finally, mutant SOD1
aggregates interact with Derlin-1, a member of the ERAD pathway, and disrupts the proteasome-dependent degradation of misfolded ER proteins, thus promoting
further ER stress. For further details please refer to the main text.
indicative of unfolded proteins has been shown to accumulate
in the ER of motor neurons of sporadic ALS patients (Sasaki,
2010). In line with ER stress and induction of the UPR, the ER
chaperone binding immunoglobulin protein/glucose-regulated
protein 78 (BiP/GRP-78) was upregulated in motor neurons of
sporadic ALS patients (Sasaki, 2010) and the levels of all three
UPR stress transducers were found to be elevated in cerebrospinal
fluid (CSF) and spinal cord of sporadic ALS patients (Atkin
et al., 2008). In addition, a number of UPR-related chaperones,
including protein disulfide isomerase (PDI) were present in CSF
and throughout the motor neurons of sporadic ALS patients
(Atkin et al., 2006, 2008). PDI has also been found in association
with SOD1-inclusions in SOD1G93A transgenic mice, and it has
been suggested that PDI is involved in the removal of these
aggregates (Atkin et al., 2006). In SOD1G93A transgenic mice
elevated UPR stress sensor levels have been observed prior to
disease onset, as early as postnatal day 5, suggesting ER stress may
be an early pathogenic event in the development of ALS (Atkin
et al., 2008; Saxena et al., 2009). In vitro, expression of mutant
SOD1A4V in the NSC-34 motor neuron-like cell line induces ER
stress and apoptosis (Walker et al., 2010).
Interestingly, exposure of primary motor neurons to the CSF
of sporadic ALS patients leads to ER stress, activation of the
UPR and neuronal degeneration (Vijayalakshmi et al., 2009,
2011). How CSF elicits ER stress and degeneration is not clear
but the process appears to involve activation of Caspase-12.
Caspase-12 is known to mediate ER stress-induced apoptosis, and
is activated by the UPR (Nakagawa et al., 2000; Martinez et al.,
2010).
Chemical induction of ER stress in NSC-34 cells led
to increased TDP-43 cleavage (Suzuki et al., 2011), while
overexpression of ALS-associated TDP-43A315T and Q331K
mutants in Neuro2a cells led to ER stress and activation of a
number of UPR stress response pathways, including increased
CHOP protein levels, increased nuclear XBP1 and increased
activation of ATF6 (Walker et al., 2013). This activation of the
UPR by mutant TDP-43 could further promote the cytoplasmic
mislocalisation of TDP-43, and therefore toxicity (Walker
et al., 2013). Similarly, expression of ALS mutant FUS and
C9orf72-associated poly-GA DPRs have been shown to induce
ER stress in NSC-34 cells and primary neurons, respectively (Farg
et al., 2012; Zhang Y.J. et al., 2014).
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Several ALS-associated proteins appear to directly interfere
with pathways required for proteostasis and/or UPR. ALS mutant
SOD1 has been shown to interact with Derlin-1, an ER protein
essential for ERAD, and perturb the ERAD pathway (Nishitoh
et al., 2008). Dysfunctional ERAD induces ER stress which
eventually triggers apoptosis via the ASK1 pathway (Nishitoh
et al., 2008). Mutations in vesicle-associated membrane protein-
associated protein B (VAPB), an integral ER protein that has been
implicated in UPR activation via the IRE1 and ATF6 pathways
cause ALS8 (Nishimura et al., 2004; Kanekura et al., 2006;
Gkogkas et al., 2008; Suzuki et al., 2009). Overexpression of ALS
mutant VAPBP56S has been shown to induce ER stress (Suzuki
et al., 2009). However, VAPB expression is down-regulated in
ALS8 patient-derived iPSC neurons due to reduced expression
of the VAPBP56S mutant (Mitne-Neto et al., 2011), therefore
it is more likely ALS-associated loss of function of VAPB may
predispose motor neurons to ER stress (Kanekura et al., 2006;
Gkogkas et al., 2008; Suzuki et al., 2009). Indeed, since knock-
down of VAPB inhibits activation of the IRE/XBP1 pathway in
response to chemical ER stressors, VAPB appears to promote
the UPR in reaction to ER stress under physiological conditions
(Kanekura et al., 2006). How VAPB regulates the UPR is not yet
clear but may involve its role in maintaining ER/mitochondria
contacts via interaction with the mitochondrial outer membrane
protein PTPIP51 (De Vos et al., 2012).
ER/mitochondria contacts allow mitochondria and ER to
communicate directly with each other via the exchange of
calcium signals (reviewed in Paillusson et al., 2016). Under
physiological conditions, mitochondrial calcium activates the
rate-limiting enzymes of the Krebs cycle and thereby increases
oxidative phosphorylation and ATP synthesis to match local
energy demand. In turn, energized mitochondria influence ER
calcium homeostasis and redox dependent ER processes such
as oxidative protein folding (reviewed in Walczak et al., 2012).
Disruption of ER/mitochondria contacts has been shown to
induce ER stress and the UPR (Simmen et al., 2005), possibly
by disturbing the variety of ER chaperones, such as BiP,
calnexin, calreticulin, ERp44, ERp57, and Sigma non-opioid
intracellular receptor 1 (Sig1R) that are present in mitochondria-
associated ER membranes (MAMs) (Hayashi and Su, 2007).
Reduced levels of VAPB have been reported in the spinal
cord of sporadic ALS cases, suggesting that ER/mitochondria
contacts and the UPR may be impaired as a consequence
(Anagnostou et al., 2010). Consistent with this possibility,
neuronal overexpression of wild type human VAPB has been
shown to slow disease and increase survival in SOD1G93A
transgenic mice (Kim et al., 2016) but whether this is
related to the restoration of the UPR and ER/mitochondria
contacts remains to be determined. Interestingly disruption of
ER/mitochondria contacts appears to be a common phenomenon
in ALS with reduced ER/mitochondria contact sites found
in mutant SOD1, Sig1R, TDP-43, and FUS-related ALS
(Lautenschlager et al., 2013; Stoica et al., 2014, 2016; Watanabe
et al., 2016).
Mutations in the SIGMAR1 gene that encodes Sig1R cause
a juvenile form of ALS (ALS16) (Al-Saif et al., 2011). Sig1R1
is an ER protein that resides at ER/mitochondria contacts
where it interacts with BiP and regulates calcium exchange
by acting as a ligand-operated receptor chaperone for the
inositol 1,4,5-trisphosphate receptor 3 (IP3R3) (Hayashi and
Su, 2007). ALS-associated loss of function of Sig1R has
been linked to dysfunctional ER/mitochondria communication
calcium dysfunction and ER stress (Prause et al., 2013; Vollrath
et al., 2014).
Mutations in the ATPase VCP cause of 1–2% of familial
ALS cases as well as inclusion body myopathy (IBM) with
Paget’s disease (PDB) and FTD (Johnson et al., 2010; Koppers
et al., 2012). Among other functions, VCP is involved in protein
degradation, ERAD, ER stress and autophagy (reviewed in
Meyer and Weihl, 2014), and pathogenic mutations have been
shown to impair mitochondrial proteostasis, attenuate ERAD and
lead to an impaired stress response (Fang et al., 2015; Wang
et al., 2016). Mutant VCP has been linked to altered TDP-43
metabolism in Drosophila (Ritson et al., 2010) and spinal cord
motor neurons of mutant VCP transgenic mice exhibit TDP-43
pathology (Custer et al., 2010). Mutant VCP expression also leads
to redistribution of wild type TDP-43 from the nucleus to the
cytoplasm in vitro and in vivo (Gitcho et al., 2009; Custer et al.,
2010; Ritson et al., 2010). Thus, the typical TDP-43 pathology
observed in ALS may be a direct consequence of dysfunctional
proteostasis.
Proteasome Dysfunction and ALS
The characteristic pathological protein accumulations seen in
ALS are indicative of defective protein clearance. In eukaryotes,
the majority of misfolded proteins are degraded by the UPS
in which poly-ubiquitin-tagged substrates are directed to and
degraded by the 26S proteasome, a multimeric ATP-dependent
protease complex comprised of the core 20S protease capped
with two 19S regulatory subunits (reviewed in Eytan et al., 1989;
Driscoll and Goldberg, 1990; Hoffman et al., 1992; Voges et al.,
1999; Ciechanover and Kwon, 2015). Evidence from both familial
and sporadic cases of ALS indicates proteasome dysfunction may
be involved in disease pathogenesis (Figure 5).
ALS mutant SOD1 has been shown to directly interact
with the 19S regulatory subunits of the proteasome, which
could contribute to the observed proteasomal inhibition seen
in multiple models of ALS (Urushitani et al., 2002; Kabashi
et al., 2004; Cheroni et al., 2005, 2009). Furthermore, reduced
expression of UPS components in the spinal cord of SOD1G93A
transgenic mice has been reported (Basso et al., 2009; Marino
et al., 2015), and ALS mutant SOD1 itself is poly-ubiquitinated
and cleared by the proteasome (Niwa et al., 2002; Urushitani
et al., 2004). Possibly, age-related reductions in UPS activity or
high demand, leads to the formation of cytotoxic mutant SOD1
inclusions (Kitamura et al., 2014).
Other familial ALS-associated proteins also support the role
of a defective UPS in the development of ALS. In addition to its
role in ERAD and ER stress discussed above, VCP is involved in
substrate delivery to the proteasome (Dai and Li, 2001; Meyer
and Weihl, 2014) and regulation of proteasome activity (Wojcik
et al., 2004; Clemen et al., 2015). ALS-associated missense
mutations in VCP have been shown to disrupt VCP-proteasome
interaction, possibly resulting in defective proteasomal clearance
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FIGURE 5 | Proteasome dysfunction in ALS. The ubiquitin proteasome system is responsible for the degradation of poly-ubiquitinated protein substrates.
Misfolded proteins are poly-ubiquitinated by the action of the E1, E2, and E3 ubiquitin ligases. Proteasome dysfunction has been implicated in ALS. Altered substrate
delivery to the proteasome, mutant protein interaction with the proteasome, as in the case of mutant SOD1, and reduced proteasome function have all been
implicated in ALS pathogenesis, ultimately leading to poly-ubiquitinated protein aggregate formation. The ALS-associated genes and their positions in the UPS are
indicated in red, as are other ALS-associated defects. Interestingly, not only can mutant SOD1 interact with the 19S subunit of the proteasome, but mutant SOD1 is
also a substrate for proteasome clearance. For further details please refer to the main text.
of ubiquitinated proteins resulting in aggregation (Barthelme
et al., 2015).
Mutations in UBQLN2 which encodes the ubiquitin-like
protein, ubiquilin-2, are associated with X-linked ALS and
ALS-dementia (Deng et al., 2011). Ubiquilin-2 is a member
of the ubiquilin family, which regulates the degradation of
ubiquitinated proteins. Patients with ubiquilin-2 mutations
display the classical ALS-associated ubiquitinated protein
aggregates, which, interestingly, are also positive for ubiquilin-2
(Deng et al., 2011). Like VCP, ubiquilin-2 is able to bind
poly-ubiquitin chains and aids in substrate delivery to the
proteasome (Ko et al., 2004). ALS-associated ubiquilin-2 mutants
are defective in proteasome binding, resulting in defective
substrate delivery to the proteasome and the accumulation of
poly-ubiquitinated proteasome substrates (Chang and Monteiro,
2015). Ubiquilin-2 has also been implicated in an autophagy
independent pathway that clears protein aggregates via the
proteasome. In this pathway, ubiquilin-2 shuttles Hsp70-bound
aggregated proteins to the proteasome to allow degradation. ALS
mutant ubiquilin-2 has lost the ability to bind to Hsp70 and this
sensitizes cells to protein stress (Hjerpe et al., 2016).
As discussed above, ALS mutant VAPB is linked with ER
stress and defective UPR. However, there is also evidence
that ALS mutant VAPB may impair the UPS. VAPBP56S is
found in cytoplasmic aggregates, which by itself could be an
indication of defective proteasome function (Suzuki et al., 2009;
Moumen et al., 2011). Expression of mutant VAPBP56S in
cells promotes the formation of ubiquitinated aggregates, as
well as the accumulation of other proteasomal substrates (Chen
et al., 2010; Moumen et al., 2011). Similarly, ubiquitinated
inclusions have been found in the spinal cord motor neurons of
VAPBP56S transgenic mice (Tudor et al., 2010). Furthermore,
mutant VAPBP56S has been demonstrated to interact with
the 20S subunit of the proteasome, suggesting proteasome
sequestering and trapping, and therefore UPS dysfunction, could
be a contributing factor in ALS8 (Moumen et al., 2011).
Impaired proteasome function has also been reported in
sporadic ALS cases (Kabashi et al., 2012). Levels of the 20S
proteasome subunit were significantly reduced in motor neurons
of sporadic ALS cases compared to controls, and proteasomal
activity was found to be impaired in the spinal cord (Kabashi
et al., 2012). As sporadic ALS cases make up the vast majority
of clinically diagnosed ALS cases, this finding suggests that
defective proteasomal activity may explain ALS pathology and
be a contributing factor in a high percentage of ALS cases.
In this context, it is noteworthy that conditional knockout
of the proteasome subunit Rpt3 in motor neurons in mice
results in motor neuron degeneration and locomotor defects
accompanied by the accumulation of a number of ALS-related
proteins, including TDP-43, FUS and optineurin in intraneuronal
inclusions (Tashiro et al., 2012). Such inclusions are obviously
reminiscent of the classical ALS pathology, suggesting that
proteasomal dysfunction alone may be sufficient to drive the
development of ALS.
Autophagy
Autophagy is an intracellular lysosomal degradation pathway
responsible for the bulk clearance of cytoplasmic components
such as misfolded proteins and damaged organelles. Autophagy
requires the formation of a double membrane structure called the
autophagosome, which encapsulates autophagic substrates prior
to their transport to, and fusion with the lysosome (reviewed in
Bento et al., 2016). The autophagic process can be divided into
four distinct stages: (i) translocation and initiation, (ii) elongation
and recruitment, (iii) completion, and (iv) lysosome fusion and
degradation. The stages of autophagy are detailed in Figure 6.
Autophagy is essential for neuronal health. Inhibition of
autophagy in neurons by neuronal-specific knockout of essential
autophagy genes such as Atg7, Atg5, and RB1CC1 (FIP200)
causes neurodegeneration in mice in absence of any other
contributory factors (Hara et al., 2006; Komatsu et al., 2006; Liang
et al., 2010). Loss of autophagy in these mice is accompanied
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FIGURE 6 | The steps of autophagy. The four stages of autophagy are indicated. (1) Translocation of the ULK1 initiation complex to the phagophore is the first
step in autophagy initiation. Inhibition of mTOR, releases the ULK1 complex allowing activation and translocation of the complex. (2) Elongation of the phagophore
membrane is mediated by the Class III PI3 kinase complex. Cargo recruitment to the growing phagophore is mediated by the autophagy receptors,
p62/sequestosome-1 and optineurin. Autophagy receptors bind both poly-ubiquitin chains on autophagy substrates via the ubiquitin-like (Ubl) domains and LC3-II
on the growing phagophore via LC3-interacting regions (LIRs). (3) After substrate recruitment and closure, completed autophagosomes are transported to allow
fusion with the lysosome. (4) Autophagosome–lysosome fusion allows the degradation of the autophagic substrates by the action of acid hydrolases, present within
the lysosome. Degradation allows the recycling of nutrients back to the cytosol. For further details please refer to the main text. Figure adapted from Webster et al.
(2016b) under the terms of the Creative Commons Attribution License (CC BY).
by progressive deficits in motor function, including abnormal
limb-clasping reflexes (also observed in ALS mutant SOD1
transgenic mice) and a reduction in coordinated movement.
Furthermore, reminiscent of many neurodegenerative diseases
including ALS, loss of basal autophagy causes accumulation of
neuronal ubiquitin-positive cytoplasmic inclusion bodies (Hara
et al., 2006; Komatsu et al., 2006; Liang et al., 2010). Basal
neuronal autophagy appears to be especially required for the
maintenance of axons as loss of autophagy causes axonal
dystrophy (Komatsu et al., 2006).
Defective Autophagy in ALS
Growing evidence supports a role of defective autophagy in the
pathogenesis of ALS. As discussed above, ubiquitinated inclusion
bodies are a neuropathological hallmark of ALS, suggesting
autophagy may be compromised. Both SOD1 and TDP-43
are autophagy substrates, and compromised autophagy causes
accumulation of mutant SOD1 and TDP-43 (Kabuta et al., 2006;
Hetz et al., 2009; Wang et al., 2010; Brady et al., 2011; Barmada
et al., 2014). Consistent with a block in autophagic flux, the levels
of LC3-II are increased in SOD1G93A and H46R transgenic mice
(Li et al., 2008; Hadano et al., 2010) as well as C9orf72 knockout
mice (O’Rourke et al., 2016). However, it has to be noted that
increased LC3-II levels may also be the result increased induction
of autophagy in response to protein aggregation. Induction of
autophagy using trehalose enhanced SOD1 clearance in NSC-34
cells and protected SOD1G93A transgenic mice (Castillo et al.,
2013). Genetic induction of autophagy by XBP-1 knockout also
extended lifespan in SOD1G93A transgenic mice (Hetz et al.,
2009; Matus et al., 2009). Conversely, heterozygous deletion of
Beclin-1 exacerbated disease in SOD1G127X transgenic mice
(Tokuda et al., 2016). Autophagy enhancers increased TDP-
43 turnover and prevented cell death in ALS mutant TDP-
43 expressing cell lines but in vivo data are not yet available
(Barmada et al., 2014).
There appears to be a regulatory feedback loop between
TDP-43 and autophagy. TDP-43 has been shown to regulate
the transcription of the essential autophagy gene Atg7 (Bose
et al., 2011). Loss of TDP-43 decreases Atg7 mRNA levels,
in turn causing impairment of autophagy and accumulation
of ubiquitinated proteins and p62/sequestosome-1. TDP-43, as
well as FUS, regulate transcription of HDAC6 which, along
with its binding partner p62/sequestosome-1, plays an important
role in the clearance of protein aggregates by aggrephagy
(reviewed in Lamark and Johansen, 2012), such that loss of
TDP-43 or FUS dramatically reduces the level of HDAC6
mRNA (Fiesel et al., 2010; Kim et al., 2010; Xia et al., 2015).
Hence cytoplasmic aggregation of TDP-43/FUS, and associated
loss of function, decreases Atg7 and HDAC6 expression and
consequently autophagy while, conversely, reduced autophagy
promotes TDP-43/FUS aggregation, in a perpetuating toxic loop.
The Function of ALS Genes in Autophagy
Several familial ALS genes function at different stages in the
autophagy pathway (Figure 7).
Initiation
The most common genetic cause of ALS and FTD is a
hexanucleotide repeat expansion of GGGGCC in the first
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FIGURE 7 | Autophagy dysfunction and ALS. Many ALS-associated genes, indicated in red, are implicated in the autophagy pathway. The location of gene
names indicates the likely part of the pathway affected in ALS. Protein aggregates are a common feature of ALS pathology. The autophagy cargoes detailed here
include a number of ALS-associated proteins, namely SOD1 and TDP-43, both of which are considered autophagy substrates. Mutant forms of these proteins,
alterations to the pathway as a whole, or aberrant production of autophagy substrates, potentially in the case of C9orf72-related DPR proteins, may disrupt efficient
substrate clearance, overwhelming the autophagy pathway and further promoting autophagy dysfunction. Importantly, TDP-43 is also important for autophagy gene
transcription, thus participating as both a substrate and a regulator of the autophagy. For further details please refer to the main text. Figure adapted from Webster
et al. (2016b) under the terms of the Creative Commons Attribution License (CC BY).
intron of the C9ORF72 gene (collectively termed C9ALS/FTD)
(DeJesus-Hernandez et al., 2011; Renton et al., 2011). The
pathogenic mechanisms behind this repeat expansion have been
reviewed elsewhere, but may include toxic gain-of-function,
namely via RNA toxicity and DPR formation, or alternatively
loss-of-function via C9ORF72 haploinsufficiency (reviewed in
Cooper-Knock et al., 2015; Haeusler et al., 2016). With evidence
for all three mechanisms in patients and a range of models, it
is likely that all three mechanisms are at play. We and others
have recently identified the C9orf72 protein as a regulator of
autophagy (Amick et al., 2016; Sellier et al., 2016; Sullivan et al.,
2016; Webster et al., 2016a; reviewed in Webster et al., 2016b;
Yang et al., 2016). We found that C9orf72 is an effector of
Rab1a that facilitates trafficking of the ULK1 initiation complex
to the phagophore during autophagy initiation (Webster et al.,
2016a) while others demonstrated that a complex of C9orf72,
SMCR8, and WDR41 acts as a guanine nucleotide exchange
factor for RAB8a and RAB39b further down the autophagy
pathway during autophagosome maturation (Sellier et al., 2016).
Furthermore, the C9orf72/SMCR8/WDR41 complex was shown
to interact with the autophagy receptor optineurin (itself a Rab8a
interactor) and TBK1, a well-known regulator of autophagy
(Sellier et al., 2016). Both optineurin and TBK1 have been
shown to be mutated in ALS cases (Table 1). Loss of C9orf72
in neurons inhibited autophagy and caused accumulation of
p62/sequestosome-1 (Sellier et al., 2016; Webster et al., 2016a)
while C9ALS/FTD patient-derived iNeurons exhibited reduced
basal autophagy levels compared to controls (Webster et al.,
2016a). Thus, these data predict that C9orf72 haploinsufficiency
impairs autophagy. Consistent with compromised autophagy,
C9ALS/FTD patients characteristically exhibit ubiquitin and
p62/sequestosome-1 positive, TDP-43 negative, inclusions in the
cerebellum and hippocampus (Al-Sarraj et al., 2011; Cooper-
Knock et al., 2012; Mahoney et al., 2012).
In addition to C9orf72, another Rab GTPase-associated
protein associated with autophagy is involved in ALS. Alsin
is a GDP/GTP exchange factor for the small GTPase Rab5
(Topp et al., 2004). Rab5 is involved in autophagy initiation
via activation of the Vps34 complex and the recruitment of the
ATG12–ATG5 conjugation system required for autophagosome
formation (Ravikumar et al., 2008; Figure 7). Pathogenic
missense mutations in ALS2 lead to loss of Alsin function,
reduced Vps34 activation, defective autophagosome formation,
and ultimately the development of ALS (Hadano et al.,
2001, 2010; Otomo et al., 2011). Consistent with a role
in autophagosome formation, genetic ablation of Alsin in
SOD1H46R transgenic mice exacerbated disease and enhanced
accumulation of a range of autophagy substrates including
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mutant SOD1 aggregates, poly-ubiquitinated proteins, and
p62/sequestosome-1 (Hadano et al., 2010).
Delivery of substrates to the autophagosome
Autophagy receptors deliver cargoes to the forming
autophagosome by binding to both ubiquitinated substrates
and LC3-II via ubiquitin-associated (UBA) and LC3-interacting
region (LIR) domains, respectively. Autophagy receptors are
crucial for effective substrate clearance (reviewed in Stolz et al.,
2014). Mutations in the autophagy receptors, ubiquilin-2,
optineurin, and p62/sequestosome-1 have been shown to cause
ALS (Fecto et al., 2011; Hirano et al., 2013; Teyssou et al., 2013;
Chen et al., 2014; Majcher et al., 2015; Figure 7). These mutations
appear to be loss-of function mutations that impair delivery of
substrates to the autophagosome.
Mutations in ubiquilin-2, which have been found in both
sporadic and familial ALS, lead to the incorporation of
ubiquilin-2 into cytoplasmic aggregates in the brain and
spinal cord (Deng et al., 2011). These aggregates are also
positive for other ALS-related proteins, including TDP-43 and
ubiquitin. Furthermore, ubiquilin-2 has been shown to interact
directly with TDP-43 (Cassel and Reitz, 2013), suggesting
that the mislocalisation of TDP-43 and its incorporation
into cytoplasmic aggregates could be a product of defective
autophagic clearance. Wild type ubiquilin-2 co-localizes with
optineurin on p62/sequestosome-1 and ULK1 positive vesicles
during autophagy induction (Osaka et al., 2015). However,
the ALS-associated mutant ubiquilin-2 is absent from these
optineurin positive vesicles, indicating a potential loss of function
mechanism, and supporting the idea that ALS-associated
mutations in ubiquilin-2 cause autophagic clearance defects
(Osaka et al., 2015).
ALS-associated mutations within the OPTN gene lead to
the increased formation of cytoplasmic aggregates, which are
immunoreactive for optineurin itself (Maruyama et al., 2010;
Ito et al., 2011; Korac et al., 2013; Weishaupt et al., 2013). The
E478G mutation is found within the ubiquitin binding domain
of optineurin, suggesting that, at least in the case of this mutant,
substrate binding and therefore autophagosomal delivery may
be compromised (Maruyama et al., 2010). It has also been
reported that mutant optineurin can sequester and “trap” wild
type proteins leading to defective autophagosome maturation,
and therefore defective clearance (Shen et al., 2015).
ALS-associated mutations in p62/sequestosome-1 map to the
LIR domain (Chen et al., 2014). One of these mutations, L341V,
was shown to disrupt interaction with LC3-II (Goode et al., 2016),
supporting the idea that p62/sequestosome-1 mutations disturb
the delivery of autophagic substrates to the autophagosome.
However, the effect of other mutations on the function of
p62/sequestosome-1 and their effects on autophagy are yet to be
determined.
The activities of p62/sequestosome-1 and optineurin
are, in part, regulated by TBK1. Phosphorylation by TBK1
increases interaction of p62/sequestosome-1 and optineurin
with LC3-II and/or ubiquitin chains, and increases autophagic
clearance (Weidberg and Elazar, 2011; Wild et al., 2011;
Matsumoto et al., 2015; Richter et al., 2016). As mentioned
above, TBK1 also interacts with the C9orf72/SMCR8/WDR41
complex and phosphorylates SMCR8, but the significance
of this phosphorylation is not yet clear (Sellier et al., 2016).
Haploinsufficiency of TBK1 has been shown to cause ALS,
likely by compromising its regulatory function in autophagy
(Freischmidt et al., 2015).
Maturation
As previously discussed, VCP mutations have been found in both
sporadic and familial ALS (Table 1). Although, VCP was initially
identified as being involved in proteasome substrate delivery – see
above (Dai and Li, 2001), there is also evidence supporting a role
in autophagy. Reduced VCP activity leads to impaired maturation
of autophagosomes and thus accumulation of ubiquitin and
p62/sequestosome-1-positive aggregates (Ju et al., 2009; Tresse
et al., 2010). VCP is also linked to two other ALS-associated
proteins, TDP-43 and FUS. Both TDP-43 and FUS are involved
in stress granule formation, cytoplasmic sites of stalled mRNA
translation that form in response to stress (Buchan and Parker,
2009; Colombrita et al., 2009; Dormann et al., 2010; Bentmann
et al., 2012). Mutant TDP-43 and FUS readily accumulate into
stress granules (Bosco et al., 2010; Baron et al., 2013; Vance et al.,
2013; Walker et al., 2013) and VCP and autophagy have been
linked to stress granule clearance (Buchan et al., 2013).
FIG4 regulates the cellular levels of phosphatidylinositol-3,5-
bisphosphate (PIP2), a signaling lipid required in autophagy
(Ferguson et al., 2009). FIG4 mutations lead to ALS potentially by
a loss of function mechanism (Chow et al., 2009). FIG4 knockout
in mice leads to the accumulation of p62/sequestosome-1 and
LC3-II, suggesting reduced autophagosome clearance could be at
play in FIG4-related ALS (Ferguson et al., 2009).
Dynactin, a multimeric protein complex, interacts with
cytoplasmic dynein to bring about retrograde transport of cargos
(Waterman-Storer et al., 1997). Multiple point mutations in
the p150 subunit of dynactin (DCTN1; dynactin-1) are found
in a number of neurodegenerative diseases, including ALS
(Puls et al., 2003; Münch et al., 2004, 2005; Vilariño-Güell
et al., 2009). The ALS-associated mutations in dynactin may
disrupt dynein–dynactin interactions, leading to aggregation
of mutant dynactin and its respective cargos (Levy et al.,
2006). Autophagosome transport in neurons is regulated by
the dynein–dynactin complex and therefore disruption of this
complex may lead to aberrant autophagosome transport and
protein aggregation (Ravikumar et al., 2005; Maday et al.,
2012; Maday and Holzbaur, 2014). In support of this, knock
down of dynactin-1 in Caenorhabditis elegans causes motor
defects, axonal degeneration and impaired transport and
subsequent accumulation of autophagosomes (Ikenaka et al.,
2013). Furthermore, reduced expression of dynactin-1 has been
reported in sporadic ALS, suggesting alterations to the dynactin
complex and disrupted autophagosome transport could be a
common pathogenic mechanism in ALS (Jiang et al., 2007;
Kuzma-Kozakiewicz et al., 2013).
Degradation
Missense mutations in the charged multivesicular body protein
2B (CHMP2B) gene is associated with FTD and predominantly
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lower motor neuron ALS (Skibinski et al., 2005; Parkinson et al.,
2006; Cox et al., 2010). The CHMP2B protein is part of the
endosomal sorting complex required for transport-III (ESCRT-
III) (Bodon et al., 2011), which sorts ubiquitinated protein
substrates from endosomes to the lysosomes by the formation of
multivesicular bodies (MVBs) (reviewed in Williams and Urbe,
2007). Efficient autophagic degradation requires the formation
of functional MVBs (Filimonenko et al., 2007). Interestingly,
loss of ESCRT-III members or expression of mutant CHMP2B
leads to the accumulation of autophagosome markers such
as p62/sequestosome-1 and LC3-II consistent with reduced
lysosomal clearance (Filimonenko et al., 2007; Lee et al., 2007;
Urwin et al., 2010). Indeed impaired fusion events between the
autophagosome and the lysosome has been demonstrated in
HEK293 cells overexpressing mutant CHMP2B (Urwin et al.,
2010).
Further evidence of defective autophagosome–lysosome
fusion and clearance comes from the study of patients harboring
mutations in SPG11, which encodes the Spatacsin protein.
Deletions and frameshift mutations in SPG11, lead to hereditary
spastic paraplegia (HSP) as well as juvenile recessive ALS
(Orlacchio et al., 2010). Autophagosome accumulation in mutant
SPG11 patient fibroblast cells indicates that loss of spatacsin
results in reduced clearance, potentially due to reduced lysosome
biogenesis (Chang et al., 2014; Renvoisé et al., 2014). Data
from mutant SPG11 patient-derived iPSC neurons also indicates
that loss of spatacsin may lead to impaired axonal transport,
suggesting a convergence of pathogenic mechanisms (Pérez-
Brangulí et al., 2014).
MODULATING PROTEOSTASIS TO
TREAT ALS
The evidence discussed above strongly suggests that protein
aggregation due to collapse of proteostasis may contribute to the
etiology of ALS. Thus, restoring proteostasis to reduce aggregated
protein burden has emerged as an attractive therapeutic target.
Several pathways in the proteostasis network are amenable
to pharmaceutical intervention and have been targeted in
experimental models. To date, treatments have focused on either
increasing protein folding to prevent protein aggregation or
removal of aggregated proteins (Table 2).
Upregulation of Chaperone Function
As discussed above, molecular chaperones play an essential role
in the proteostasis network. They are upregulated in response
to protein stress (e.g., by the UPR), and thus are amenable to
regulation. Furthermore, evidence suggests that inhibition of
chaperone activity may contribute to ALS.
Hydroxylamine derivatives, such as Arimoclomol stabilize
the transcription factor heat shock factor protein 1 (HSF-1)
in its active state leading to its prolonged activation
and the upregulation of a number of heat shock family
chaperones, including Hsp60, Hsp70, and Hsp90 (Vígh
et al., 1997). Arimoclomol has been shown to delay disease
progression, extend lifespan, increase muscle function, and
prevent aggregation of mutant SOD1 in SOD1G93A mouse
models of ALS (Kieran et al., 2004; Kalmar et al., 2008,
2012). Importantly, HSF-1 does not bind its corresponding
DNA elements in the absence of cellular stress. Thus, the
prolonged activation of HSF-1 by hydroxylamine derivatives
only enhances the heat shock response in already stressed
cells, therefore mitigating the potentially toxic induction
of the heat shock response and chaperone upregulation
in otherwise healthy cell populations (Hargitai et al.,
2003).
In a similar fashion to Arimoclomol, treatment with the
Hsp90 inhibitor 17-AAG activates Hsp70 reducing the number of
pathological TDP-43 aggregates in HEK293T cells overexpressing
aggregation-prone TDP-43 C-terminal fragments (Chang et al.,
2013).
Treatments Targeting the UPR
ER stress appears to be involved in ALS pathogenesis.
Accordingly, the UPR which alleviates ER stress under
physiological conditions may be an attractive therapeutic
target.
The PERK branch of the UPR leads to phosphorylation of the
eukaryotic translational initiation factor eIF2α which decreases
global protein synthesis and up-regulates the translation of
selected stress-induced mRNAs such as the transcription factor
ATF4. ATF4 induces expression of genes involved in amino acid
metabolism, resistance to oxidative stress, and the proapoptotic
transcription factor CHOP (Figure 3). The ER stress inhibitors
salubrinal and guanabenz prevent eIF2α dephosphorylation
and keep eIF2α in its inactive state (Boyce et al., 2005;
Tsaytler et al., 2011). Salubrinal treatment protected SOD1G93A
transgenic mouse motor neurons from ER stress (Saxena
et al., 2009) and treatment of SOD1G93A transgenic mice
with guanabenz delayed onset of disease, attenuated motor
neuron loss and significantly extended lifespan (Jiang et al.,
2014; Wang et al., 2014). In contrast, others have shown
that guanabenz treatment accelerated disease progression in
SOD1G93A transgenic mice (Vieira et al., 2015). The reason
for these opposing findings is not clear, but may be attributable
to differences in study design (discussed in Vieira et al.,
2015). Both guanabenz and salubrinal attenuated ER stress and
reduced paralysis and neurodegeneration in mutant TDP-43
Caenorhabditis elegans and zebrafish models of ALS (Vieira et al.,
2015).
Perhaps counter-intuitively, conditional knockout of XBP-1
was shown to extend the survival of female SOD1G86R
transgenic mice (Hetz et al., 2009). However, in this model,
abrogation of the UPR coincided with increased autophagic
clearance of SOD1 aggregates, suggesting that a lower
aggregated protein burden elicits the protective effect of
XBP-1 knockout (Hetz et al., 2009). Similarly, knockout of
ATF4 also delayed disease onset and prolonged life span in
SOD1G86R transgenic mice. ATF4 deficiency completely
prevented the induction of pro-apoptotic genes, but increased
SOD1 aggregation suggesting that, in this case, prevention
of UPR-induced apoptosis mediated protection (Matus et al.,
2013).
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Increasing Degradation of Misfolded
Proteins and Aggregates
While increasing protein folding may help to reduce the
pathological protein accumulations in ALS, an alternative
approach is to promote their degradation by activation of the UPS
and/or autophagy.
Proteasome Activation
Pyrazolone-containing small molecules have been shown to block
ALS mutant SOD1 mediated cytotoxicity and aggregation in a
number of studies (Chen et al., 2012; Trippier et al., 2012; Zhang
et al., 2013). The mechanism of action of pyrazolone was shown
to be by activation of the proteasome, suggesting that proteasome
activators may be of therapeutic benefit in ALS (Trippier et al.,
2014). However, the protective action of pyrazolones has only
been tested in mutant SOD1-related ALS models, and as such
more studies are needed to test the efficacy of these small
molecules in other ALS models.
Enhancing Autophagy
Most attempts to modulate autophagy as a treatment for ALS
have been aimed at enhancing the removal of aggregated proteins
by stimulating autophagic flux. In vitro, three potent inducers
of autophagy, fluphenazine, methotrimeprazine and 10-(4′-(N-
diethylamino)butyl)-2-chlorophenoxazine, efficiently enhance
ALS mutant TDP-43A315T aggregate clearance and improved
survival of murine primary cortical neurons overexpressing
TDP-43A315T as well as iPSC-derived motor neurons and
astrocytes carrying the pathogenic M337V TDP-43 mutation
(Barmada et al., 2014). Similarly, the traditional medicinal
herb and known inducer of autophagy, berberine, increased
clearance of EGFP-tagged aggregation-prone C-terminal TDP-
43 fragments, and reduced insoluble TDP-43 aggregates in
transfected Neuro2a cells (Chang et al., 2016). In vivo, a number
of mTOR-dependent (rapamycin, tamoxifen) and independent
(spermidine, carbamazepine) autophagy enhancers have been
shown to reduce TDP-43 aggregation, rescue learning/memory
and slow motor deficits in an FTLD-U mouse model with
transgenic overexpression of TDP-43 in the hippocampus, cortex,
and striatum (Wang et al., 2012). Hence induction of autophagy
may be of therapeutic benefit to clear ALS-associated TDP-43
aggregates.
Activating autophagy may also be beneficial in the removal
of mutant SOD1 aggregates. Trehalose, an mTOR independent
activator of autophagy, has been shown to reduce the aggregation
of SOD1G85R in the spinal cord of SOD1G85R transgenic mice,
an effect that was accompanied by increased lifespan and delayed
disease onset in these mice (Castillo et al., 2013). Similar results
were reported in SOD1G93A transgenic mice (Zhang X. et al.,
2014), although the efficacy of trehalose may decline as the
TABLE 2 | Restoring protein homeostasis as a treatment for ALS.
Target Treatment Effect on proteostasis Effect on disease Reference
HSF-1 Arimoclomol Stabilizes HSF-1. Upregulation of
chaperones
Delays disease progression and increases
lifespan in SOD1G93A mice
Kieran et al., 2004;
Kalmar et al., 2008
Hsp90 17-AAG Hsp90 inhibition and Hsp70 activation Reduces TDP-43 aggregates in HEK293 cells Chang et al., 2013
UPR/eIF2α Salubrinal eIF2a maintained in active state and
persistence of UPR
Protection of SOD1G93A mice MN from ER
stress
Boyce et al., 2005
UPR/eIF2α Guanabenz eIF2a maintained in active state and
persistence of UPR
Delayed disease onset, extended lifespan and
reduced MN loss of SOD1G93A mice
Tsaytler et al., 2011
Chronic UPR XBP-1 knockout Inhibition of UPR. Increased autophagic
clearance
Extends survival in SOD1G86R mice and
reduced SOD1 aggregation
Hetz et al., 2009
Chronic UPR ATF4 knockout Complete inhibition of UPR
pro-apoptotic gene expression
Delayed disease onset and extends survival in
SOD1 G86R mice. Increased SOD1
aggregation
Matus et al., 2013
UPS Pyrazolone Proteasome activation Reduced SOD1G93A cytotoxicity and
aggregation
Chen et al., 2012;
Trippier et al., 2012;
Zhang et al., 2013
Autophagy Fluphenazine
methotrimeprazineNCP
Autophagy induction Enhance mutant TDP-43A315T clearance,
improved survival of murine primary cortical
neurons overexpressing TDP-43A315T
Barmada et al., 2014
Autophagy Berberine Autophagy induction Increased clearance of aggregate prone
TDP-43 fragments in N2a cells
Chang et al., 2016
Autophagy Rapamycin/tamoxifen mTOR dependent autophagy induction Reduces TDP-43 aggregation, rescues
memory/learning and slow motor deficits in
FTLD-U mouse
Wang et al., 2012
Autophagy Spermidine/carbamazepine mTOR independent autophagy
induction
Reduced TDP-43 aggregation, increased
memory/learning and reduced slow motor
deficits in FTLD-U mouse
Wang et al., 2012
Autophagy Trehalose mTOR independent autophagy
induction
Reduced SOD1G85R aggregation in spinal
cord of SOD1G85R mice, delaying onset and
increasing lifespan
Castillo et al., 2013;
Zhang X. et al., 2014;
Li et al., 2015
MN, motor neurons.
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disease progresses (Li et al., 2015). In contrast to trehalose,
mTOR dependent induction of autophagy using rapamycin has
either no effect (Staats et al., 2013) or exacerbates disease in
SOD1G93A transgenic mice (Zhang et al., 2011). This effect of
rapamycin may stem from its function as an immunosuppressant,
because rapamycin treatment did increase survival in SOD1G93A
transgenic mice lacking mature lymphocytes (Staats et al., 2013).
DISCUSSION AND OUTLOOK
Collapse of proteostasis and resulting protein aggregation is
a universal feature of ALS as discussed above. Most evidence
suggest that protein aggregation is deleterious for cells and,
by extension, this may also be the case in ALS. In agreement,
boosting clearance of protein aggregates and/or preventing
protein aggregation appears to be of benefit in animal models
of ALS. However, it has been suggested that protein aggregation
may be a protective mechanism. By compartmentalization of
the toxic misfolded proteins the cell prevents them from
causing damage, e.g., to mitochondria or to proteostasis by
sequestering chaperones and blocking the UPS. Furthermore,
compartmentalization may facilitate clearance by aggrephagy.
Thus, some caution is warranted when devising treatments to
prevent protein aggregation.
Proteostasis is a universal process in every cell, not just
neurons. Before embarking on long term treatment with for
example autophagy enhancers, possible side effects need to be
considered. For example, evidence from the cancer field indicates
that in most cases autophagy facilitates tumorigenesis (reviewed
in White, 2015). Similarly, inhibition of the PERK branch of the
UPR may seem a good idea in principle but balancing the UPR
appears to be critical for neuronal integrity, and long-term PERK
inhibition may not be feasible due to considerable side effects
(Scheper and Hoozemans, 2013). Furthermore, is important to
take into account the genetic background of individual ALS
patients when considering employing modulators of protein
quality control as a treatment of disease. For example, treating
patients with a known autophagosome clearance defect with
autophagy enhancers would not be likely to be beneficial and may
even be deleterious.
Nevertheless, results from ALS models and models of other
neurodegenerative diseases such as Huntington’s disease indicate
that treatments targeting proteostasis and in particular autophagy
have great potential. Further understanding of the genetics of
ALS and the mechanisms of proteostasis dysfunction associated
with ALS will be vital if proteostasis modulators are to be used
effectively as neuroprotective therapies.
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